OREANDA-NEWS. TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today presented two TRC105-focused posters at the 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (IASLC) in Yokohama, Japan. The posters included initial clinical data from a study of TRC105 with Avastin and chemotherapy in first-line lung cancer and the trial design of the Phase 1b trial of TRC105 and Opdivo in second-line lung cancer.

A Phase 1b Study of TRC105 in Combination with Paclitaxel/Carboplatin and Bevacizumab in Patients with Stage 4 Non-Squamous Cell Lung Cancer

Initial data from nine patients in the ongoing single center, open-label, non-randomized study were presented by Dr. Francisco Robert and colleagues from the University of Alabama-Birmingham:

  • Partial responses by RECIST 1.1 occurred in 3 of 8 (37%) evaluable patients, including one patient who had an 81% reduction in tumor volume.
  • Dose escalation of TRC105 from 8 mg/kg to 10 mg/kg proceeded without dose-limiting toxicity.
  • Adverse events characteristic of each drug did not increase in frequency or severity when the drugs were administered concurrently.
  • The trial continues to enroll and the complete enrollment of approximately 18 patients is expected by the end of 2018.

In addition, investigators at the University of Alabama-Birmingham presented a “trials in progress” poster related to the ongoing Phase 1b dose-escalation study of TRC105 and Opdivo® (nivolumab) in patients with metastatic non-small cell lung cancer. The trial is now open for accrual.

Both posters are available on TRACON’s website at: www.traconpharma.com/publications.php

About Carotuximab (TRC105)

TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in a pivotal Phase 3 trial in angiosarcoma and multiple Phase 2 clinical trials, in combination with VEGF inhibitors. TRC105 has received orphan designation for the treatment of soft tissue sarcoma in both the U.S. and EU. The ophthalmic formulation of TRC105, DE-122, is currently in a randomized Phase 2 trial for patients with wet AMD. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.


TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer.